How is selinesol used to treat diffuse large B lymphoma?

Selinexor (Selinexor) has demonstrated significant efficacy and unique advantages in the treatment of diffuse largeB cell lymphoma (DLBCL).

Selinesol, as the world's first approved oral selective nuclear export protein inhibitor (SINE), inhibits nuclear export protein 1 (XPO1), promoting the nuclear retention and activation of tumor suppressor proteins and other growth regulatory proteins, thereby inducing tumor cell apoptosis. In multiple clinical studies, selinesol has shown good anti-tumor activity, bringing new hope to patients with relapsed or refractory (R/R) DLBCL. Specifically, selinesol can significantly improve patients' response rate and prolong survival, which is of great significance for patients with R/R DLBCL with poor prognosis.

Selinesol's mechanism of action is different from other traditional chemotherapy drugs. It mainly exerts anti-tumor effects by inhibitingXPO1. XPO1plays an important role in DLBCL disease progression and is associated with poor patient prognosis. By inhibiting XPO1, selinesol can promote the accumulation and activation of tumor suppressor proteins in the nucleus, thereby inhibiting the proliferation and spread of tumor cells. In addition, selinesol can also down-regulate the levels of various oncogenic proteins in the cytoplasm, further enhancing its anti-tumor effect.

As an oral drug, selinesol is very convenient to use. Patients do not need to be hospitalized and only need to take it orally on time. This not only reduces the physical burden on patients, but also reduces treatment costs. At the same time, selinesol has relatively low side effects, making it easier for patients to tolerate treatment. In clinical trials, selinesol has shown a low incidence of adverse reactions, and most adverse reactions are mild to moderate and can be alleviated with appropriate supportive care.

Selinesol has shown good efficacy in patients with different subtypes ofDLBCL, including germination centerB cells or non-germination centerBCellular tumor subtypes and patients with dual or triple expression status. This provides new treatment options for patients of different subtypes and is expected to improve their prognosis and quality of life.